Clinical trial
SP16 Inflammatory Response Inhibition Trial
NCT04225533 is registered in ClinicalTrials.gov with Serpin Pharma, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SP16 Inflammatory Response Inhibition Trial
- Lead sponsor
- Serpin Pharma, LLC
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 24, 2020
- Completion date
- December 21, 2021
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.